First-quarter results from Bristol Myers Squibb beat expectations, but the stock finished roughly flat Thursday amid mounting ...

A team of researchers at UT Southwestern Medical Center is aiming to find treatments for diseases of the cerebellum, a fist-sized structure in the back of the brain ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Across the U.S., some people with mental illness wait months in jail for court-ordered competency evaluations, with little to ...

The pharmaceutical company on Thursday said it raised its full-year guidance for revenue in the year to a range of $45.8 billion to $46.8 billion, up from a previous forecast of $45.5 billion.

As a psychiatric provider working with people from all walks of life, I’ve seen how serious mental health conditions, ...

Neumora Therapeutics, Inc.’s NMRA share price has surged by 10.34%, which has investors questioning if this is right time to sell.

ALL Vishalatchi Arunagiri wants is for people with mental health issues to have equal opportunities and to enjoy inclusivity ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Further, it provides a sense of dignity and self-worth for patients by giving them a sense of making a valuable contribution.